Management of Lipids in Patients with Diabetes

被引：9
作者：
Mbue, Ngozi D. [1 ,2 ,3 ]
Mbue, John E. [2 ]
Anderson, Jane A. [1 ,2 ,3 ]
机构：
[1] Hlth Sci Res & Dev Ctr Innovat Qual Effectiveness, 152,2002 Holcombe Blvd, Houston, TX 77030 USA
[2] Michael E DeBakey VA Med Ctr, 152,2002 Holcombe Blvd, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
来源：
NURSING CLINICS OF NORTH AMERICA | 2017年 / 52卷 / 04期
关键词：
Diabetes; Lipids; Nursing; Practice applications; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN PARTICLES; CARDIOVASCULAR-DISEASE; LDL CHOLESTEROL; COLESEVELAM HYDROCHLORIDE; PRIMARY PREVENTION; DOUBLE-BLIND; APOLIPOPROTEIN-B; GLYCEMIC CONTROL; ARTERY-DISEASE;
D O I：
10.1016/j.cnur.2017.07.009
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Abnormal lipids, sometimes referred to as diabetes dyslipidemia, is a common condition in patients with diabetes. With the increasing number of patients with abnormal lipids, especially those with type 2 diabetes, health care practitioners, including nurses, must properly manage patients with diabetes as well as abnormal lipids. This article examines the pathophysiology of abnormal lipids, the management of abnormal lipids, and the lipid goals for patients with diabetes. Last, this article discusses pharmacologic and nonpharmacologic therapies and the role of primary care providers and nurses in the management of abnormal lipids.
引用
收藏
页码：605 / +
页数：17
相关论文
共 87 条
  • [1] AHA/ACC, 2013, CHOL TREATM GUID NOV
  • [2] Introduction
    不详
    [J]. DIABETES CARE, 2017, 40 : S1 - S130
  • [3] Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
    Athyros, VG
    Papageorgiou, AA
    Athyrou, VV
    Demitriadis, DS
    Kontopoulos, AG
    [J]. DIABETES CARE, 2002, 25 (07) : 1198 - 1202
  • [4] AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
  • [5] ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK
    AUSTIN, MA
    KING, MC
    VRANIZAN, KM
    KRAUSS, RM
    [J]. CIRCULATION, 1990, 82 (02) : 495 - 506
  • [6] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
    Baigent, C.
    Blackwell, L.
    Emberson, J.
    Holland, L. E.
    Reith, C.
    Bhala, N.
    Peto, R.
    Barnes, E. H.
    Keech, A.
    Simes, J.
    Collins, R.
    [J]. LANCET, 2010, 376 (9753) : 1670 - 1681
  • [7] How Advances in Genomics are Changing Patient Care
    Bancroft, Elizabeth K.
    [J]. NURSING CLINICS OF NORTH AMERICA, 2013, 48 (04) : 557 - +
  • [8] Management of lipids in patients with diabetes
    Barnett, A
    [J]. DIABETES OBESITY & METABOLISM, 2003, 5 : S3 - S9
  • [9] Statin Use for the Primary Prevention of Cardiovascular Disease in Adults US Preventive Services Task Force Recommendation Statement
    Bibbins-Domingo, Kirsten
    Grossman, David C.
    Curry, Susan J.
    Davidson, KarinaW.
    Epling, John W., Jr.
    Garcia, Francisco A. R.
    Gillman, Matthew W.
    Kemper, Alex R.
    Krist, Alex H.
    Kurth, Ann E.
    Landefeld, C. Seth
    LeFevre, Michael L.
    Mangione, Carol M.
    Phillips, William R.
    Owens, Douglas K.
    Phipps, Maureen G.
    Pignone, Michael P.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19): : 1997 - 2007
  • [10] Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study
    Bruckert, E
    Hayem, G
    Dejager, S
    Yau, C
    Bégaud, B
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) : 403 - 414
123456789